We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status.
- Authors
Aspite, Silvia; Schepis, Filippo; Roccarina, Davide; Gitto, Stefano; Citone, Michele; Di Bonaventura, Chiara; Bianchini, Marcello; Arena, Umberto; Vannucchi, Alessandro M.; Guglielmelli, Paola; Campani, Francesca; Fanelli, Fabrizio; Marra, Fabio; Vizzutti, Francesco
- Abstract
In patients affected by myelofibrosis with hepatic myeloid metaplasia (HMM), portal hypertension (PHT) complications may develop. In this case series, we analysed the efficacy and safety of transjugular portosystemic shunt (TIPS) in the treatment of PHT‐related complications and its effects on the nutritional status. Six patients were evaluated and the average follow‐up period after TIPS was 33 (IQR 5) months. None of the patients developed hepatic failure, nor any recurrence of variceal bleeding was recorded. No additional paracentesis or endoscopic prophylactic treatment for PHT‐related complications were required. In all subjects, the average dose of diuretics was almost halved three months after TIPS. Three patients died during the follow‐up, but none for liver‐related causes. All patients showed an improvement in the global nutritional status. In conclusion, TIPS represent an effective and safe treatment option for patients affected by complications of PHT secondary to HMM and drives to an improvement of the nutritional status.
- Subjects
MYELOID metaplasia; NUTRITIONAL status; PORTAL hypertension; THERAPEUTIC complications; PARACENTESIS; LIVER failure
- Publication
Liver International, 2022, Vol 42, Issue 2, p419
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.15148